Valbiotis : Commercialisation of “Valbiotis®PRO Cholesterol” in France planned for May
>Totum-070 arrives on the French market in May 2024...as planned - In line with the previously announced targets, the group is to launch, on the French market, its first food supplement “Valbiotis®PRO Cholesterol”, composed entirely of Lipidrive® (ex-TOTUM 070), for the treatment of light to moderate hypercholesterolemia in May 2024. The drug will be promoted through in-house medical promotion officers (MPO) and will be available in pharmacies as well as on the compan...Valbiotis SA Formerly known as Valbiotis SAS. Valbiotis SA is a France-based company engaged in the biotechnology industry. The Company specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. It seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The Company prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. It provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.